Not COVID-19, Don't Overlook Pneumocystis in Patients on Gefitinib!
Fiche publication
Date publication
février 2021
Journal
Current oncology (Toronto, Ont.)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr QUIPOURT Valérie
Tous les auteurs :
Barben J, Quipourt V, Vovelle J, Putot A, Manckoundia P
Lien Pubmed
Résumé
An 82-year-old woman treated for advanced lung cancer with gefitinb was admitted to the emergency unit complaining of dyspnea. Chest computed tomography found abnormalities classified as possible diffuse COVID-19 pneumonia. RT-PCR for Sars-Cov-2 was twice negative. PCR for Pneumocystis jirovecii was positive on bronchoalveolar lavage. The final diagnosis was Pneumocystis jirovecii pneumonia. Therefore, physicians must be careful not to misdiagnose COVID-19, especially in cancer patients on small-molecule therapeutics like gefitinib and corticosteroids.
Mots clés
COVID-19, gefitinib, pneumocystis jirovecii, tyrosine-kinase inhibitor
Référence
Curr Oncol. 2021 Feb 21;28(1):961-964